首页|中西医结合治疗乙肝肝硬化伴顽固性腹水的临床疗效研究

中西医结合治疗乙肝肝硬化伴顽固性腹水的临床疗效研究

扫码查看
目的 探讨中西医结合治疗乙型病毒性肝炎(乙肝)肝硬化伴顽固性腹水的临床疗效.方法 120 例乙肝肝硬化伴顽固性腹水患者,应用随机数字表法分为对照组和研究组,每组 60 例.对照组应用常规西医治疗,研究组应用中西医结合治疗.比较两组患者临床疗效、症状消退时间、不良反应发生情况、血清炎性因子、症状评分、生活质量评分.结果 研究组临床总有效率 98.33%较对照组的 86.67%高,差异明显(P<0.05).研究组腹胀、乏力、腹痛消退时间分别为(4.12±0.76)、(3.29±0.81)、(4.37±0.89)d,均比对照组的(5.30±0.93)、(4.32±0.97)、(5.64±1.02)d短,差异明显(P<0.05).两组不良反应发生率对比,无明显差异(P>0.05).治疗后,两组C反应蛋白、白细胞介素-6 水平对比于治疗前均明显降低,且研究组患者C反应蛋白(5.89±1.06)mg/L、白细胞介素-6(21.83±2.17)pg/ml均比对照组的(7.02±1.27)mg/L、(25.49±2.76)pg/ml低,差异明显(P<0.05).治疗后,两组腹胀、乏力、腹痛评分对比于治疗前均明显降低,且研究组患者腹胀评分(1.17±0.39)分、乏力评分(1.06±0.31)分、腹痛评分(1.16±0.40)分均比对照组的(1.58±0.43)、(1.52±0.48)、(1.61±0.45)分低,差异明显(P<0.05).治疗后,两组生理、心理、环境、社会关系评分对比于治疗前均明显升高,且研究组患者生理评分(89.75±6.48)分、心理评分(89.07±6.02)分、环境评分(90.14±6.15)分、社会关系评分(89.96±6.27)分均比对照组的(82.93±6.85)、(82.40±6.13)、(83.27±6.30)、(83.14±6.54)分高,差异明显(P<0.05).结论 应用中西医结合治疗乙肝肝硬化伴顽固性腹水患者,可起到加快症状缓解、减轻炎症反应等作用,疗效显著,有助于改善患者生活质量,且中西医结合治疗的不良反应未增多,具有良好的安全性.
Clinical curative effect of integrated traditional Chinese and Western medicine in treating cirrhosis with refractory ascites
Objective To explore the clinical efficacy of integrated traditional Chinese and Western medicine in treating cirrhosis with refractory ascites.Methods A total of 120 patients with cirrhosis with refractory ascites were divided into a control group and a study group according to the method of random number table,with 60 cases in each group.The control group was treated with conventional Western medicine,and the study group was treated with integrated traditional Chinese and Western medicine.The clinical efficacy,symptom subsidence time,adverse reactions,serum inflammatory factors,symptom score and quality of life were compared between the two groups.Results The total clinical effective rate of the study group was 98.33%,which was higher than the control group's 86.67%,and the difference was significant(P<0.05).The subsidence time of abdominal distension,fatigue and abdominal pain in the study group were(4.12±0.76),(3.29±0.81)and(4.37±0.89)d,which were shorter than(5.30±0.93),(4.32±0.97)and(5.64±1.02)d in the control group,and the difference was significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).After treatment,the levels of C-reactive protein and interleukin-6 in both groups were significantly reduced compared with those before treatment;the study group had C-reactive protein of(5.89±1.06)mg/L and interleukin-6 of(21.83±2.17)pg/ml,which were lower than(7.02±1.27)mg/L and(25.49±2.76)pg/ml in the control group;the difference was significant(P<0.05).After treatment,the scores of abdominal distension,fatigue and abdominal pain in both groups were significantly reduced compared with those before treatment;the study group had abdominal distension score of(1.17±0.39)points,fatigue score of(1.06±0.31)points and abdominal pain score of(1.16±0.40)points,which were lower than(1.58±0.43),(1.52±0.48)and(1.61±0.45)points in the control group;the differences were significant(P<0.05).After treatment,the scores of physiology,psychology,environment and social relations in both groups were significantly higher than those before treatment;the study group had physiology score of(89.75±6.48)points,psychology score of(89.07±6.02)points,environment score of(90.14±6.15)points and social relation score of(89.96±6.27)points,which were all higher than(82.93±6.85),(82.40±6.13),(83.27±6.30)and(83.14±6.54)points in the control group;the difference was significant(P<0.05).Conclusion In the treatment of cirrhosis with refractory ascites,the therapy of integrated traditional Chinese and Western medicine can accelerate the relief of symptoms and reduce the inflammatory reaction,and help improve the quality of life of patients,and the adverse reactions of integrated Chinese and western medicine have not increased.So is has good safety.

Hepatitis BHepatitis B cirrhosisRefractory ascitesIntegrated traditional Chinese and Western medicineChinese medicine

宋铭悦

展开 >

271000 泰安市中医医院

乙型病毒性肝炎 肝硬化 顽固性腹水 中西医结合治疗 中医学

山东省中医药科技项目

2020Q105

2024

中国实用医药
中国康复医学会

中国实用医药

影响因子:0.797
ISSN:1673-7555
年,卷(期):2024.19(10)
  • 15